| Document Date: 2014-07-17 15:20:46
Open Document File Size: 136,58 KBShare Result on Facebook
City San Francisco / / Company ViaCyte Inc. / / Currency USD / / / Event FDA Phase / / Facility California Institute / / IndustryTerm cell-based technologies / durable and retrievable encapsulation device / Diabetes Therapy / treatment of diabetes / implantable product / / MedicalCondition disease / diabetes / tremendously difficult disease / / MedicalTreatment drug delivery system / cell therapy / / Organization Food and Drug Administration / JDRF JDRF / California Institute for Regenerative Medicine / / Person Paul Laikind / C. Randal Mills / Jonathan Thomas / Kevin McCormack / / / Position President and CEO of the stem cell agency / president and CEO / Chair / Chair of the agency’s governing Board / / Product Investigational New Drug / T1D / / ProvinceOrState California / / Technology cell therapy / cell-based technologies / drug delivery system / stem cells / Regenerative Medicine / / URL www.jdrf.org / www.viacyte.com / www.cirm.ca.gov / /
SocialTag |
Microsoft Word - CIRM News release ViaCyte IND PL LB[2].docx